Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
Martens CR, Denman BA, Mazzo MR, et al. (2018). Nature Communications.
Summary
A crossover trial in healthy middle-aged and older adults testing whether the NAD+ precursor nicotinamide riboside is tolerated and whether it actually raises NAD+ in people. It was well tolerated and did stimulate NAD+ metabolism. On physiological function the authors report initial signals rather than conclusions, suggesting that future trials look specifically at blood pressure and arterial stiffness. Target engagement demonstrated; clinical benefit not.